The Taiwan government has been promoting policies to develop the biotechnology industry since the 1980s. According to the Biotechnology and Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs, Taiwan's biotechnology/pharmaceutical industry in is valued at US$20 billion in 2020, a 7.4% growth from 2019, while the revenue of the pharmaceutical sector has reached US$3 billion, a 4.09% growth from 2019. By August 2021, there were 129 listed companies, 65 in the emerging stock market, and 18 companies on the Taiwan Innovation Board.

Lumosa's Naldebain(R) injection, an analgesic that offers up to 7 days of pain relief, was one of few medicines that received international market authorization; other drugs with this status include PharmaEngine's Onivyde(R), PharmaEssentia's Besremi(R), and Panion & BF Biotech's Nephoxil(R).

https://industry-update.com/taiwans-top-10-biotech-companies/103889/